| Q33471229 | A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer |
| Q38748641 | Antitumour actions of interferons: implications for cancer therapy |
| Q36589103 | Central Nervous System Toxicity of Biological Response Modifiers |
| Q41096129 | Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse |
| Q40743081 | Immuno-chemotherapy of advanced colorectal cancer with alpha-2a interferon and 5-fluorouracil. Immunopharmacological studies |
| Q42526603 | Influence of low-dose beta-interferon on natural killer cell activity in breast cancer patients subjected to chemotherapy |
| Q43478082 | Interferon in the treatment of cancer. |
| Q38210046 | Interferons: biological and clinical effects |
| Q38164278 | Interferons: current status and future directions of this prototypic biological |
| Q41704863 | Modulation by oestrogen and progestins/antiprogestins of alpha interferon receptor expression in human breast cancer cells |
| Q35991589 | Recombinant DNA human interferon alpha 2 in advanced breast cancer: a phase 2 trial |
| Q44860591 | Recombinant gamma interferon in advanced breast cancer: a phase II trial |
| Q41149795 | Recombinant human interferon alpha increases oestrogen receptor expression in human breast cancer cells (ZR-75-1) and sensitizes them to the anti-proliferative effects of tamoxifen |
| Q40808971 | Safety and tolerance of recombinant interferon alfa-2a (Roferon-A) in cancer patients |
| Q38171061 | The antitumor effects of interferon. |
| Q39747611 | The evolving role of alpha interferon in the treatment of malignancies |
| Q38208932 | The role of interferons in the treatment of malignant neoplasms |